Attributes | Values |
---|
rdf:type
| |
Description
| - Mutation or epigenetic silencing of the transcription factor C/EBP alpha is observed in similar to 10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBP alpha whereby its expression is inversely correlated with C/EBP alpha activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBP alpha mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBP alpha inactivation contributes to the development of leukemia with a distinct LIC phenotype.
- Mutation or epigenetic silencing of the transcription factor C/EBP alpha is observed in similar to 10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBP alpha whereby its expression is inversely correlated with C/EBP alpha activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBP alpha mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBP alpha inactivation contributes to the development of leukemia with a distinct LIC phenotype. (en)
|
Title
| - Sox4 is a key oncogenic target in C/EBP alpha mutant acute myeloid leukemia
- Sox4 is a key oncogenic target in C/EBP alpha mutant acute myeloid leukemia (en)
|
skos:prefLabel
| - Sox4 is a key oncogenic target in C/EBP alpha mutant acute myeloid leukemia
- Sox4 is a key oncogenic target in C/EBP alpha mutant acute myeloid leukemia (en)
|
skos:notation
| - RIV/68378050:_____/13:00422959!RIV14-AV0-68378050
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| - Alberich-Jorda, Meritxell
|
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/13:00422959
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Sox4; C/EBP alpha; acute myeloid leukemia (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Zhang, H.
- Zhang, J.
- Yang, H.
- Amabile, G.
- Delwel, R.
- DiRuscio, A.
- Tenen, D. G.
- Ye, M.
- Alberich-Jorda, Meritxell
- Bonifer, C.
- Cammenga, J.
- Ebralidze, A.
- Hoogenkamp, M.
- Lefebvre, V.
- Levantini, E.
- Nerlov, C.
- Saez, B.
- Scadden, D. T.
- Staber, P. B.
- Valk, P. J.
- Welner, R. S.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1016/j.ccr.2013.09.018
|